Form 4: Daxor CSO Jonathan Feldschuh Granted 18,000 Shares

Daxor Corp's Chief Scientific Officer and Director, Jonathan Feldschuh, was granted 18,000 shares of common stock, which will vest on December 9, 2025.

Summary

• Jonathan Adam Feldschuh, Chief Scientific Officer, Director, and 10% Owner of Daxor Corp (DXR), was granted 18,000 shares of Daxor Common Stock.
• The transaction occurred on December 9, 2025.
• The shares were granted at a price of $0, indicating an equity award.
• These 18,000 shares are scheduled to vest on December 9, 2025.
• Following this transaction, Feldschuh beneficially owns a total of 53,908 shares of Daxor Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of shares to a key executive is a positive signal of management alignment and retention, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of shares to a key executive and director aligns management's interests with shareholders.
• The vesting schedule provides an incentive for long-term commitment and performance.
• The transaction was made under a Rule 10b5-1(c) plan, indicating a pre-planned and transparent equity award.

Future Outlook

The grant of shares with a future vesting date suggests an ongoing commitment to the company's long-term performance and executive retention.

Industry Context

Equity grants to key executives are a standard practice across industries, particularly in biotechnology and medical device sectors like Daxor, to incentivize leadership and align their financial interests with company performance and shareholder value creation.

Comparison to Industry Standards

• The grant of equity to a Chief Scientific Officer and Director is a common compensation practice, comparable to similar roles in small to mid-cap biotech and medical technology companies.
• The use of a Rule 10b5-1 plan for such transactions is a standard corporate governance practice, enhancing transparency and mitigating concerns about insider trading.

Corporate Governance

Related Party Transactions

• The grant of 18,000 shares of common stock to Jonathan Adam Feldschuh, a Director, Chief Scientific Officer, and 10% Owner, constitutes a related party transaction as part of his compensation.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a key executive with shareholders, potentially fostering long-term value creation.
• Employees: May signal stability in leadership and a commitment to retaining key talent.

Next Steps

• The 18,000 granted shares will vest on December 9, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a positive for management alignment but does not provide new fundamental information to warrant a change in investment recommendation. It reinforces the 'hold' position based on existing company fundamentals.

Keywords

Daxor Corp, DXR, Jonathan Feldschuh, Chief Scientific Officer, Director, stock grant, equity award, insider ownership, Form 4, beneficial ownership, vesting, Rule 10b5-1